MA71666A - Compositions d'agent d'arni de stéaroyl-coa désaturase 5 (scd5) et procédés d'utilisation associés - Google Patents
Compositions d'agent d'arni de stéaroyl-coa désaturase 5 (scd5) et procédés d'utilisation associésInfo
- Publication number
- MA71666A MA71666A MA71666A MA71666A MA71666A MA 71666 A MA71666 A MA 71666A MA 71666 A MA71666 A MA 71666A MA 71666 A MA71666 A MA 71666A MA 71666 A MA71666 A MA 71666A
- Authority
- MA
- Morocco
- Prior art keywords
- scd5
- stearoyl
- methods
- rnai agent
- agent compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14212—Pumping with an aspiration and an expulsion action
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/19—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with oxidation of a pair of donors resulting in the reduction of molecular oxygen to two molecules of water (1.14.19)
- C12Y114/19001—Stearoyl-CoA 9-desaturase (1.14.19.1), i.e. DELTA9-desaturase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163162788P | 2021-03-18 | 2021-03-18 | |
| US202163278389P | 2021-11-11 | 2021-11-11 | |
| PCT/US2022/020825 WO2022197975A1 (fr) | 2021-03-18 | 2022-03-17 | Compositions d'agent d'arni de stéaroyl-coa désaturase 5 (scd5) et procédés d'utilisation associés |
| EP22772237.8A EP4308130A4 (fr) | 2021-03-18 | 2022-03-17 | Compositions d'agent d'arni de stéaroyl-coa désaturase 5 (scd5) et procédés d'utilisation associés |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA71666A true MA71666A (fr) | 2025-05-30 |
Family
ID=83320836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA71666A MA71666A (fr) | 2021-03-18 | 2022-03-17 | Compositions d'agent d'arni de stéaroyl-coa désaturase 5 (scd5) et procédés d'utilisation associés |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20240200077A1 (fr) |
| EP (1) | EP4308130A4 (fr) |
| MA (1) | MA71666A (fr) |
| WO (1) | WO2022197975A1 (fr) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1633770B1 (fr) * | 2003-06-13 | 2015-04-29 | Alnylam Europe AG | Acide ribonucleique double brin presentant une efficacite accrue dans un organisme |
| US20070161003A1 (en) * | 2003-09-29 | 2007-07-12 | Morris David W | Novel therapeutic targets in cancer |
| NZ594995A (en) * | 2009-03-12 | 2013-06-28 | Alnylam Pharmaceuticals Inc | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUMAN KINESIN FAMILY MEMBER 11 (Eg5) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENES |
| CN103361352A (zh) * | 2013-07-31 | 2013-10-23 | 扬州大学 | 鹅原代肝细胞scd1基因沉默试剂盒及其应用 |
| EP3566055B1 (fr) * | 2017-01-06 | 2025-03-12 | Janssen Pharmaceutica NV | Inhibiteurs de la scd pour le traitement de troubles neurologiques |
-
2022
- 2022-03-17 MA MA71666A patent/MA71666A/fr unknown
- 2022-03-17 US US18/550,669 patent/US20240200077A1/en active Pending
- 2022-03-17 EP EP22772237.8A patent/EP4308130A4/fr active Pending
- 2022-03-17 WO PCT/US2022/020825 patent/WO2022197975A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4308130A4 (fr) | 2025-09-17 |
| EP4308130A1 (fr) | 2024-01-24 |
| WO2022197975A1 (fr) | 2022-09-22 |
| US20240200077A1 (en) | 2024-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4329757A4 (fr) | Composés hétérocycliques et procédés d'utilisation | |
| MA52390A (fr) | Anticorps anti-coronavirus et procédés d'utilisation | |
| EP3890736A4 (fr) | Agents de dégradations de petites molécules de helios et procédés d'utilisation | |
| EP4153564A4 (fr) | Dérivés de tryptamine deutérés et procédés d'utilisation | |
| EP4125831A4 (fr) | Inhibiteurs de kcnt1 et procédés d'utilisation | |
| EP3958872A4 (fr) | Compositions d'oligonucléotides et leurs procédés d'utilisation | |
| EP3962479A4 (fr) | Inhibiteurs de kcnt1 et procédés d'utilisation | |
| EP3941475A4 (fr) | Pyridazinones et leurs procédés d'utilisation | |
| EP4208445A4 (fr) | Dérivés de psilocybine halogénés et leurs procédés d'utilisation | |
| EP3969460A4 (fr) | Dérivés d'ascaroside et procédés d'utilisation | |
| EP3917543A4 (fr) | Compositions de nitrate améliorées et procédés d'utilisation | |
| EP4423205A4 (fr) | Compositions de polissage et leurs procédés d'utilisation | |
| EP4034605A4 (fr) | Compositions de polissage et leurs procédés d'utilisation | |
| EP3996714A4 (fr) | Formulations d'inhibiteurs de rbp4 et procédés d'utilisation | |
| EP4297871A4 (fr) | Procédés et compositions pour le traitement de l'agitation | |
| EP4161921A4 (fr) | Inhibiteurs de traduction du collagène 1 et leurs procédés d'utilisation | |
| EP4319813A4 (fr) | Multimères de peptide-mhc-immunoglobuline et leurs procédés d'utilisation | |
| EP4346815A4 (fr) | Composés hétérocycliques et procédés d'utilisation | |
| EP4370537A4 (fr) | Compositions comprenant des peptides multi-agonistes, procédés de fabrication et méthodes d'utilisation | |
| EP4259178A4 (fr) | Compositions et procédés d'extension de demi-vie | |
| MA71666A (fr) | Compositions d'agent d'arni de stéaroyl-coa désaturase 5 (scd5) et procédés d'utilisation associés | |
| EP4175624A4 (fr) | Inhibiteurs de kcnt1 et procédés d'utilisation | |
| EP4294454A4 (fr) | Peptides anti-viraux et compositions et procédés d'utilisation associés | |
| EP3752517A4 (fr) | Agents de dégradation de kinase dépendante de la cycline et procédés d'utilisation | |
| MA50798A (fr) | Procédés d'utilisation et compositions contenant du dulaglutide |